PAP
ADPT icon

Persistent Asset Partners’s Adaptive Biotechnologies ADPT Stock Holding History

Persistent Asset Partners’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$92.8K Hold
6,689
– – 0.03% 243
2025
Q4 		$109K Buy
+6,689
New +$109K 0.05% 262

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Persistent Asset Partners's ADPT Position: Q1 2026 in Review

Persistent Asset Partners held its Adaptive Biotechnologies (ADPT) position steady in Q1 2026 at 6,689 shares worth $92.8K. The position accounts for 0.03% of the portfolio, ranked #243.

Persistent Asset Partners first reported a position in ADPT in Q4 2025 and has held it in 2 quarters since. The position peaked at $109K in Q4 2025. 295 funds tracked by Wall St. Rank hold ADPT as of Q1 2026.

  • Persistent Asset Partners held 6,689 shares of Adaptive Biotechnologies worth $92.8K as of Q1 2026.
  • Persistent Asset Partners left its Adaptive Biotechnologies share count unchanged in Q1 2026.
  • Adaptive Biotechnologies made up 0.03% of Persistent Asset Partners's portfolio in Q1 2026, its #243 holding.
  • Persistent Asset Partners first reported a position in Adaptive Biotechnologies in Q4 2025 and has held it in 2 quarters since.
  • Persistent Asset Partners's Adaptive Biotechnologies position peaked at $109K in Q4 2025.
  • 295 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.